Strategic Investment Privately held with backing from Apple Tree Partners and a $43M funding profile, Gala Therapeutics presents a venture-backed opportunity for strategic partnerships, co-development, or potential investment-aligned sales discussions with hospital systems and research organizations focused on pulmonary disease devices.

Clinical Focus Product portfolio targets interventional pulmonology, thoracic surgery, and physicians treating pulmonary diseases such as lung cancer, COPD, and chronic bronchitis, indicating sales potential with major academic medical centers, COPD programs, and lung cancer care networks.

Early Market Activity RheOx system launched for chronic bronchitis with early feasibility studies and patient enrollment; first US patient milestones and board leadership changes signal an evolving clinical strategy and potential timing windows for converting investigational devices to reimbursed clinical usage.

Regulatory and Adoption Readiness Private status and involvement in early feasibility studies suggest readiness to engage with hospitals and device procurement teams; leverage conversations around clinical outcomes, operator training, and integration into existing interventional workflows.

Sales Enablement Small to mid-sized team size (11-50 employees) combined with a venture-backed growth profile implies a need for targeted, outcome-driven value propositions, physician champions, and measurable pilots to accelerate adoption within pulmonary disease treatment programs.